Trial Profile
The SYNBioSe Study A proof-of-concept study involving synergetic B-cell imunnomodulation in patients with refractory systemic lupus erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Rituximab (Primary)
- Indications Systemic lupus erythematosus
- Focus Proof of concept; Therapeutic Use
- Acronyms Synbiose
- 27 Jun 2020 Results assessing long-term effects of RTX + BLM on depletion of ANAs, B-cell repopulation and clinical response during two years of followup published in the Nephrology Dialysis Transplantation
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 26 Feb 2019 Status changed from recruiting to completed.